AstraZeneca strengthens partnership with the University of Cambridge
AstraZeneca, together with its global biologics research and development arm, MedImmune, today announced that it has entered into four new collaborations with the University of Cambridge, building further on their existing partnership.
Positive results from Phase IIb benralizumab study in severe asthma published
AstraZeneca today announced that The Lancet Respiratory Medicine has published positive safety and efficacy data from a Phase IIb study evaluating benralizumab, a novel investigational monoclonal antibody, in patients with severe, uncontrolled asthma and elevated levels of eosinophils, a type of inflammatory white blood cell.
AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress
AstraZeneca will present new data from its pipeline of investigational cancer medicines over the next three days at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid.
MOVENTIG® (naloxegol) receives positive CHMP opinion in the EU
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of MOVENTIG® (naloxegol), an investigational, peripherally-acting mu-opioid receptor antagonist (PAMORA), for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response…
IRESSA receives CHMP positive opinion to include blood based diagnostic testing in Euro label
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on a Type-II variation update* to the European label for IRESSA® (gefitinib).
MedImmune and Cancer Research UK establish joint lab to develop new biologic cancer medicines
AstraZeneca today announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK.
FDA fast track designation for development of MEDI3902 for prevention of nosocomial pneumonia
AstraZeneca has announced that its global biologics research and development arm, MedImmune, has received fast track designation from the US Food and Drug Administration (FDA) for its investigational monoclonal antibody (mAb) MEDI3902 for the prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa (P. aeruginosa).
28-week results from AstraZeneca's DURATION-NEO-1 Phase III study
Study showed AstraZeneca’s exenatide once-weekly suspension for autoinjection provided superior HbA1c reductions vs. twice-daily exenatide (Byetta®) in adults with type 2 diabetes.
FDA approves MOVANTIK™ (naloxegol) tablets C-II
AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK™ (naloxegol) tablets C-II as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.
Alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease
AstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.
AstraZeneca & Redx Pharma: research collaboration targeting genetic drivers of tumour growth
AstraZeneca today announced that it has entered into a research collaboration with Redx Pharma Limited to discover and develop new molecules targeting a genetic driver of tumour growth and survival.
Data indicates Brilique™ has flexibility to be initiated pre-hospital/STEMI patients
AstraZeneca today announced the results of the Phase IV ATLANTIC study, which indicates that the profile of BRILIQUE™/BRILINTA™ (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients.
AstraZeneca announces partnership with Illumina
AstraZeneca today announced that it has entered into a collaboration with gene sequencing company, Illumina Inc., to develop its next generation sequencing (NGS) platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio.
AstraZeneca and Mitsubishi Tanabe Pharma Corporation announce research collaboration
AstraZeneca and Mitsubishi Tanabe Pharma Corporation (MTPC) today announced a three-year research collaboration in the area of diabetic nephropathy. The aim of the research collaboration is to leverage complementary strengths, expertise and assets to validate and progress novel research targets and molecules into clinical development
Positive top-line results from Phase III antibiotic programme
AstraZeneca today announced positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalised adult patients with complicated intra-abdominal infections.
AstraZeneca advances tralokinumab to Phase III in severe asthma
AstraZeneca today announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm.
Results from Phase III programme of lesinurad in combination with xanthine oxidase inhibitors
AstraZeneca announces top-line results from the Phase III programme of lesinurad in combination with xanthine oxidase inhibitors in gout patients.
AstraZeneca and Kyowa Hakko Kirin partner on immuno-oncology clinical study
AstraZeneca today announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours.
AstraZeneca agrees strategic transaction with Almirall in respiratory disease
Business combination will provide boost to revenue as well as creating long-term value, strengthening AstraZeneca’s respiratory franchise with a complementary pipeline and inhaled device capabilities in asthma and COPD.
AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291
AstraZeneca today announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small-cell lung cancer (NSCLC).
AstraZeneca & QIAGEN enter collaboration to develop diagnostic test for lung cancer patients
AstraZeneca today announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA®.
Seven pharma companies offer up compounds to UK researchers
UK researchers will be granted access to a ‘virtual library’ of deprioritised pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global drug companies, announced today by Business Secretary Vince Cable.
MedImmune and Advaxis partner on immuno-oncology combination clinical trial
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.
AstraZeneca reveals designs for new global R&D centre and corporate headquarters in Cambridge
AstraZeneca today revealed the proposed designs for its new global R&D centre and corporate headquarters in Cambridge. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre[1].
AstraZeneca and Max Planck Institute announce research agreement
AstraZeneca today announced an agreement with the Max Planck Institute of Molecular Physiology (MPI), Germany, to establish a ‘satellite unit’ in cardiovascular and metabolic disease (CVMD), linked to AstraZeneca’s CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.